NCT07061704 - Oncolytic Virus in Esophageal Squamous Cell Carcinoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions

Esophageal Cancer

Interventions

BIOLOGICAL

Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses.

Oncolytic Virus: Administered via intratumoral injection once every 3 weeks, for a total of two doses, or until disease progression, the occurrence of unacceptable toxicity, or death from any cause, whichever occurs first. Chemotherapy + Immune Checkpoint Inhibitor (ICI): Administered via intravenous infusion once every 3 weeks.

Trial Locations (1)

610041

RECRUITING

West China Hospital of Sichuan University, Chengdu

All Listed Sponsors

lead

Sichuan University

OTHER